1st Patient Enrolls in Phase 2 Study of Oral Therapy, OPRX-106, for Ulcerative Colitis
News
Protalix BioTherapeutics recently announced that the first patient has been enrolled in the Phase 2 clinical trial evaluating the safety, efficacy and properties of its lead drug candidate, OPRX-106, for the ... Read more